CDA | Evidence Driven
CDA | Evidence Driven

Brentuximab Vedotin (Adcetris) for Hodgkin lymphoma in combination with doxorubicin, vinblastine, and dacarbazine - Details

Details

Files
Generic Name:
Brentuximab Vedotin
Project Status:
Complete
Therapeutic Area:
Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD)
Manufacturer:
Seattle Genetics, Inc.
Brand Name:
Adcetris
Project Line:
Reimbursement Review
Project Number:
PC0214-000
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Strength:
50 mg
Tumour Type:
Lymphoma
Indications:
Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD)
Funding Request:
For the treatment of previously untreated patients with Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD).
Sponsor:
Seattle Genetics, Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Brentuximab Vedotin (Adcetris) HL AVD – pERC Final Recommendation Final Recommendation December 3, 2020 View PDF
Brentuximab Vedotin (Adcetris) HL AVD – Final Economic Guidance Report Guidance Report December 3, 2020 View PDF
Brentuximab Vedotin (Adcetris) HL AVD – Final Clinical Guidance Report Guidance Report December 3, 2020 View PDF
Brentuximab Vedotin (Adcetris) HL AVD – pERC Initial Recommendation Initial Recommendation October 1, 2020 View PDF
Brentuximab Vedotin (Adcetris) HL AVD – PAG Feedback on Initial Recommendation Feedback December 3, 2020 View PDF
Brentuximab Vedotin (Adcetris) HL AVD – Manufacturer Feedback on Initial Recommendation Feedback December 3, 2020 View PDF
Brentuximab Vedotin (Adcetris) HL AVD – Clinician Feedback on Initial Recommendation Feedback December 3, 2020 View PDF
Brentuximab Vedotin (Adcetris) HL AVD – Patient Advocacy Group COI Declarations COI Declarations December 3, 2020 View PDF
Brentuximab Vedotin (Adcetris) HL AVD – Clinician COI Declarations COI Declarations December 3, 2020 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : December 18, 2020